Upstream Bio, Inc. (UPB)
NasdaqGS
Price as at 1 Oct 2026, 03:19 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Upstream Bio, Inc. trades at $5.27. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
7 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Israel Englander, MILLENNIUM MANAGEMENT LLC$7.91M · 0.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$7.17M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$3.77M · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$3.13M · 0.0% of book
- Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$2.48M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own UPB?
7 of the institutions we track reported a position in UPB in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its UPB data?
Fundamentals for UPB come from company filings and exchange data, as listed on NasdaqGS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 03:19 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for UPB, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.